NanoKTN and The Wellcome Trust Collaborate on Second Nano4Life Conference

The area of bio-nanotechnology is developing rapidly and there is no doubt that it will enhance our understanding of biology and how biological systems work. Nanotechnology is already being used to help resolve some of the pharma and biotech industries' significant problems and this one-day conference and exhibition, taking place in London on February 4th, will look at the ways nanotechnology in healthcare can ensure the UK is kept a leading force in this exciting area of technology.



Last year’s event saw the attendance of 150 industry and academic professionals discuss a number of key issues such as improvements in drug discovery processes, through miniaturisation, automation, speed and reliability.



The keynote presentation at the 2010 event will be delivered by Sir William Castell, Chairman of the Board of Governors at The Wellcome Trust and Board Director of both GE and BP. Other presentations come from Pharmidex Pharmaceutical Services Ltd, NIHR Office for Clinical Research Infrastructure (NOCRI), The Royal Institution and QantuMDx.



“Nanotechnology holds the promise to provide a significant number of healthcare advances and by hosting the Nano4Life conference, we aim to explore the ways in which the technology can be developed and adopted,” explains Dr Mike Fisher, Theme Manager at the NanoKTN.



Fisher continues, “Nano4Life aims to showcase the latest developments in nanotechnology to the science community and provides an environment to catalyse new collaborations. By hosting Nano4Life, the NanoKTN aims to bring together clinicians, academic scientists and industry professionals to drive forward the development of these advances.”



Nano4Life is be organised in partnership with The Wellcome Trust, the largest charity in the UK which spends over £600 million each year to support and promote research to improve the health of humans and animals.



The Trust funds research into all aspects of biology and medicine: from molecules and cells vital to life, through the spread of diseases or the vectors of disease across the globe, to clinical and public health research that can improve the quality of healthcare delivered to people. The Trust is interested in the development of hypothesis driven research which realises an unmet need in biomedical sciences and healthcare. The conference is an opportunity to showcase nanotechnology to the basic science community and provides an environment to catalyse new collaborations.